A Regenerative Regulatory Post
The FDA uses the term “homologous use” to determine if a stem cell therapy stays under the less regulated HCT/P framework or becomes subject to drug-like regulations. This is a major factor in whether a clinic can offer a treatment without going through the formal drug approval process.
But what does homologous use mean in practice?
Homologous Use Defined:
According to the FDA, homologous use means the stem cells are being used for the same basic function in the recipient as they served in the donor. For example, if fat-derived stem cells are used for cushioning or support (as fat does in the body), that’s homologous.
Non-Homologous Use:
If those same fat-derived stem cells are instead used to treat conditions like neurological disorders or arthritis—functions fat doesn’t normally perform—that’s non-homologous. This kind of use typically triggers full biological drug regulations.
Why It Matters:
The FDA uses this distinction to decide whether the treatment needs to go through IND applications (Investigational New Drug) and BLA (Biologics License Application) processes. Clinics claiming homologous use may avoid this. But if their use is deemed non-homologous, they can face FDA enforcement or legal action.
Clinics sometimes make the mistake of assuming homologous use just because the cells come from the same patient. That’s not enough. It’s about function, not just origin.
Are you considering stem cell treatment or regenerative therapy? Don’t make a decision without being fully informed. Download our free expert-curated list of 20 critical questions will empower you to evaluate potential providers with confidence and help you decide on the best outcome for your health.
